BCHM.F Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 91.77 |
| 52 Week High | CHF 97.06 |
| 52 Week Low | CHF 87.51 |
| Beta | 0.72 |
| 11 Month Change | 0% |
| 3 Month Change | -0.52% |
| 1 Year Change | n/a |
| 33 Year Change | -42.86% |
| 5 Year Change | n/a |
| Change since IPO | 818.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| BCHM.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -9.0% | -2.1% |
| 1Y | n/a | 2.9% | 29.7% |
Return vs Industry: Insufficient data to determine how BCHM.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how BCHM.F performed against the US Market.
Price Volatility
| BCHM.F volatility | |
|---|---|
| BCHM.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCHM.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BCHM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,009 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BCHM.F fundamental statistics | |
|---|---|
| Market cap | US$5.81b |
| Earnings (TTM) | US$128.58m |
| Revenue (TTM) | US$654.13m |
45.2x
P/E Ratio8.9x
P/S RatioIs BCHM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCHM.F income statement (TTM) | |
|---|---|
| Revenue | CHF 577.77m |
| Cost of Revenue | CHF 398.41m |
| Gross Profit | CHF 179.36m |
| Other Expenses | CHF 65.79m |
| Earnings | CHF 113.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 31.04% |
| Net Profit Margin | 19.66% |
| Debt/Equity Ratio | 0% |
How did BCHM.F perform over the long term?
See historical performance and comparison